Amplify Weight Loss Drug & Treatment ETF (THNR)
26.31
+0.12
(+0.47%)
USD |
NYSEARCA |
Jun 25, 16:00
26.34
+0.03
(+0.13%)
After-Hours: 20:00
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.59% | 0.15% | 2.355M | -- |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| 0.00% | -- | -- | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists (glucagon-like peptide) seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | -- |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Amplify ETFs |
| Prospectus Benchmark Index | |
| VettaFi Weight Loss Drug & Treat TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Anand Desai | 0.03 yrs |
| Dustin Lewellyn | 0.03 yrs |
| Ernesto Tong | 0.03 yrs |
Performance Versus Category
As of June 25, 2024. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of June 25, 2024.
Basic Info
| Investment Strategy | |
| The investment seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists (glucagon-like peptide) seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | -- |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Amplify ETFs |
| Prospectus Benchmark Index | |
| VettaFi Weight Loss Drug & Treat TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Anand Desai | 0.03 yrs |
| Dustin Lewellyn | 0.03 yrs |
| Ernesto Tong | 0.03 yrs |